Pfizer Inc. (NYSE:PFE) to Post Q3 2025 Earnings of $0.72 Per Share, Zacks Research Forecasts

Pfizer Inc. (NYSE:PFE) – Research analysts at Zacks Research dropped their Q3 2025 earnings per share estimates for shares of Pfizer in a research note issued on Monday, September 23rd. Zacks Research analyst K. Shah now forecasts that the biopharmaceutical company will post earnings of $0.72 per share for the quarter, down from their previous estimate of $0.73. The consensus estimate for Pfizer’s current full-year earnings is $2.66 per share.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.14. The firm had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.67 EPS.

PFE has been the topic of several other research reports. StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Wells Fargo & Company increased their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. UBS Group lifted their target price on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Finally, Barclays raised their target price on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Eight equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Pfizer currently has an average rating of “Moderate Buy” and a consensus target price of $34.54.

Pfizer Stock Down 0.4 %

PFE stock opened at $29.31 on Tuesday. Pfizer has a twelve month low of $25.20 and a twelve month high of $34.11. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $166.09 billion, a P/E ratio of -488.42, a PEG ratio of 1.05 and a beta of 0.68. The firm has a 50 day simple moving average of $29.36 and a 200-day simple moving average of $28.26.

Hedge Funds Weigh In On Pfizer

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Olistico Wealth LLC purchased a new position in Pfizer during the 2nd quarter valued at about $25,000. MFA Wealth Advisors LLC purchased a new position in Pfizer during the second quarter valued at approximately $29,000. Quarry LP acquired a new position in Pfizer in the 2nd quarter valued at approximately $31,000. Creekmur Asset Management LLC acquired a new stake in shares of Pfizer during the 4th quarter valued at $32,000. Finally, Trivant Custom Portfolio Group LLC boosted its stake in shares of Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 600 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th were issued a dividend of $0.42 per share. The ex-dividend date was Friday, July 26th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.73%. Pfizer’s dividend payout ratio is currently -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.